ZGNX - Zogenix, Inc. - NASDAQ

[eric1960]

Daily Chart:  http://stockcharts.com/h-sc/ui?s=ZGNX&p=D&b=5&g=0&id=p40266324498

Weekly Chart:  http://stockcharts.com/h-sc/ui?s=ZGNX&p=W&b=5&g=0&id=p59408107562

News:  http://finance.yahoo.com/q/h?s=ZGNX+Headlines

Business Summary:  Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company’s lead product candidate, Zohydro, is a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older.

Zogenix, Inc. markets and sells its Sumavel DosePro through field sales force primarily to neurologists and other prescribers of migraine medications, including headache clinics and headache specialists in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey; license agreement with Alkermes Plc to import, use, offer for sale, and sell tablet formulations of hydrocodone; and a co-promotion agreement with Astellas Pharma US, Inc. to market and sell Sumavel DosePro in the United States, as well as an asset purchase agreement with Aradigm Corporation. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.

[Vegas]

Don't know if you continued to follow this stock Eric but it is nearly a double bagger since December 22nd...

http://stockcharts.com/h-sc/ui?s=ZGNX&p=D&b=5&g=0&id=p37368605534

[Vegas]

Second day of decline following poor earnings estimate creates down gap...


Zogenix shares slip on weak revenue outlook

March 9, 2012

Zogenix Inc's (ZGNX.O) stock fell 20 percent, making it the top percentage loser on the Nasdaq on Friday, after the specialty pharmaceutical company forecast full-year revenue below analysts' estimates. Zogenix's outlook reflected the recent termination of the Astellas Pharma (4503.T) co-promotion agreement, which accounted for 30 percent of Sumavel DosePro sales in 2011, Leerink Swann analyst Joseph Schwartz wrote in a note to clients.

The company had said it would assume commercialization of its treatment for acute migraine and cluster headache -- Sumavel DosePro -- from the second quarter of 2012, after it ended its partnership with Astellas. For 2012, Zogenix expects revenue of $45.5 million to $48.5 million, compared with analysts' average estimates of $64.9 million, according to Thomson Reuters I/B/E/S.

http://www.reuters.com/article/2012/03/09/us-zogenix-shares-idUSBRE8280WZ20120309?feedType=RSS&feedName=globalMarketsNews&rpc=43